Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials - PubMed (original) (raw)

Clinical Trial

doi: 10.1001/archneur.61.1.59.

Ronald C Petersen, Steven H Ferris, Ronald G Thomas, Paul S Aisen, David A Bennett, Norman L Foster, Clifford R Jack Jr, Douglas R Galasko, Rachelle Doody, Jeffrey Kaye, Mary Sano, Richard Mohs, Serge Gauthier, Hyun T Kim, Shelia Jin, Arlan N Schultz, Kimberly Schafer, Ruth Mulnard, Christopher H van Dyck, Jacobo Mintzer, Edward Y Zamrini, Deborah Cahn-Weiner, Leon J Thal; Alzheimer's Disease Cooperative Study

Affiliations

Clinical Trial

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials

Michael Grundman et al. Arch Neurol. 2004 Jan.

Abstract

Background: Mild cognitive impairment (MCI) represents a transitional state between the cognitive changes of normal aging and very early dementia and is becoming increasingly recognized as a risk factor for Alzheimer disease (AD). The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD.

Objective: To describe the baseline characteristics of patients with MCI recruited for the MIS and compare them with those of elderly controls and patients with AD in another clinical trial.

Design: Descriptive and comparative study of patients with MCI participating in a multicenter clinical trial.

Setting: Memory disorder centers in the United States and Canada.

Patients: A total of 769 patients with MCI, 107 cognitively normal elderly controls, 122 patients with very mild AD (Clinical Dementia Rating [CDR] 0.5), and 183 patients with mild AD (CDR 1.0) were evaluated. Patients in the MIS met operational criteria for amnestic MCI. Controls were recruited in parallel with the MCI group, underwent the same assessments, and had a CDR of 0.

Main outcome measures: Clinical, neuropsychologic, functional, neuroimaging, and genetic measures.

Results: Mean +/- SD Alzheimer's Disease Assessment Scale-Cognitive Subscale scores were 5.6 +/- 3.3 for controls, 11.3 +/- 4.4 for patients with MCI, 18.0 +/- 6.2 for the AD CDR 0.5 group, and 25.2 +/- 8.8 for the AD CDR 1.0 group. Compared with controls, patients with MCI were most impaired on memory tasks, with less severe impairments in other cognitive domains. Patients with MCI were more likely than controls but less likely than patients with AD to carry the apolipoprotein E epsilon4 allele. Patients with MCI had hippocampal volumes that were intermediate between those of controls and patients with AD.

Conclusions: Patients with MCI had a predominant memory impairment with relative sparing of other cognitive domains and were intermediate between clinically normal individuals and patients with AD on cognitive and functional ratings. These results demonstrate the successful implementation of operational criteria for this unique group of at-risk patients in a multicenter clinical trial.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources